Eli Lilly and Company $LLY Stock Acquired by Focus Advisor Solutions LLC

Focus Advisor Solutions LLC boosted its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 69.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 23,763 shares of the company’s stock after buying an additional 9,776 shares during the period. Focus Advisor Solutions LLC’s holdings in Eli Lilly and Company were worth $27,497,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. BlackRock Inc. raised its position in shares of Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after buying an additional 1,046,558 shares in the last quarter. State Street Corp boosted its position in shares of Eli Lilly and Company by 1.7% during the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company’s stock worth $43,438,262,000 after acquiring an additional 605,752 shares in the last quarter. Bank of America Corp DE acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter worth approximately $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Eli Lilly and Company by 1.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock worth $8,647,153,000 after acquiring an additional 137,364 shares in the last quarter. Finally, Jennison Associates LLC increased its stake in Eli Lilly and Company by 7.9% in the second quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock valued at $6,550,587,000 after acquiring an additional 400,538 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Leerink Partners boosted their price objective on shares of Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the company an “outperform” rating in a research report on Wednesday, October 21st. Guggenheim upped their target price on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a research note on Friday, September 18th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $1,600.00 target price on shares of Eli Lilly and Company in a report on Tuesday. Jefferies Financial Group lifted their price target on Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the company a “buy” rating in a research note on Monday, November 9th. Finally, Morgan Stanley boosted their price target on Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,422.00.

View Our Latest Stock Analysis on LLY

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the sale, the executive vice president owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. The trade was a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Trading Down 2.4%

LLY opened at $1,380.92 on Thursday. The company’s 50 day moving average is $1,258.86 and its 200-day moving average is $1,115.99. Eli Lilly and Company has a 1-year low of $850.51 and a 1-year high of $1,475.25. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. The company has a market cap of $1.30 trillion, a P/E ratio of 44.82, a PEG ratio of 1.69 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $1.77. The company had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The firm’s revenue was up 38.6% on a year-over-year basis. During the same period in the previous year, the firm posted $7.02 EPS. Equities research analysts predict that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s payout ratio is presently 22.46%.

Key Headlines Impacting Eli Lilly and Company

Here are a few of the latest headlines about LLY:

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Featured Articles

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.